| Literature DB >> 30429240 |
Yayi Wang1, Shida Chen1, Yaoming Liu1, Wenbin Huang1, Xinyi Li1, Xiulan Zhang2.
Abstract
Acute primary angle-closure (APAC) eyes show an early 'acute inflammatory' condition, while the inflammation condition has not been fully elucidated in the development of primary angle-closure glaucoma (PACG). To evaluate the roles of inflammatory cytokines in the pathogenesis of PACG, this cross-sectional study involved 40 eyes of 32 PACG patients who required trabeculectomy and 24 eyes of 24 patients who required cataract surgery. The aqueous humor samples were collected at the time of surgery. Fifteen inflammatory cytokines were detected using the multiplex bead immunoassay technique, and the clinical information was recorded for the correlation analysis. Eight of the 15 cytokines were all detectable in both groups, including granulocyte colony-stimulating factor (G-CSF), interleukin (IL)-6, IL-8, monocyte chemotactic protein (MCP)-1, MCP-3, macrophage-derived chemokine (MDC), macrophage inflammatory protein (MIP)-1β, and vascular endothelial growth factor (VEGF). When compared with the cataract patients, the MCP-3, MDC, and VEGF levels were elevated in the PACG patients, while the MCP-1 and MIP-1β levels were decreased. However, the G-CSF, IL-6, and IL-8 levels were similar between the two groups. The MCP-1 concentration was elevated accordingly as the disease progressed in the PACG patients. Our results suggest the PACG eyes retained a 'mild inflammation' condition in the aqueous humor, and MCP-1 may play an important role in the progression of this disease.Entities:
Keywords: aqueous humor; cytokines; inflammation; primary angle-closure glaucoma
Mesh:
Substances:
Year: 2018 PMID: 30429240 PMCID: PMC6435505 DOI: 10.1042/BSR20181411
Source DB: PubMed Journal: Biosci Rep ISSN: 0144-8463 Impact factor: 3.840
Demographic and clinical characteristics of the patients
| Characteristics | PACG | Cataract | |
|---|---|---|---|
| Total no. of eyes | 40 | 24 | – |
| Age, mean (SD), year | 57.3 (10.8) | 74.0 (5.5) | <0.001 |
| Sex, no. of M/F | 18/14 | 13/11 | 0.877 |
| IOP1, mean (SD), mmHg | 24.2 (10.5) | 13.7 (3.5) | <0.001 |
| IOP2, mean (SD), mmHg | 19.7 (7.6) | 13.7 (3.5) | <0.001 |
| MD, median (IQ) | −15.8 (23.4) | – | – |
| PSD, median (IQ) | 5.5 (7.0) | – | – |
Abbreviations: IOP1, the recorded highest intraocular pressure; IOP2, the intraocular pressure measured before surgery; IQ, interquartile range; MD, mean defect; PACG, primary angle-closed glaucoma; PSD, pattern standard deviation; SD, standard deviation.
The IOP of cataract patients was only measured once before surgery, so the IOP2 is the same as IOP1.
The differences of age and IOP between the two groups were tested by two-sample independent t-test.
The difference of the sex distribution between the two groups was tested by χ2-test.
The levels of different cytokines in the aqueous
| Cytokine | PACG | Cataract | |
|---|---|---|---|
| G-CSF | 1.0 (2.1) | 1.4 (3.5) | 0.341 |
| GM-CSF | 0 | 0 | – |
| IFN-γ | 0 | 0 | – |
| IL-1β | 0 | 0 | – |
| IL-6 | 1.7 (3.6) | 5.6 (28.9) | 0.212 |
| IL-8 | 5.8 (7.5) | 6.7 (7.7) | 0.739 |
| IL-10 | 0 | 0 | – |
| MCP-1 | 905.5 (569.0) | 1154.5 (888.0) | |
| MCP-3 | 3.2 (2.1) | 0.5 (5.4) | |
| MDC | 33.5 (27.9) | 7.1 (21.1) | |
| MIP-1α | 0 | 0 | – |
| MIP-1β | 6.0 (9.8) | 10.6 (10.7) | |
| sCD40L | 0 | 0 | – |
| TNF-β | 0 | 0 | – |
| VEGF | 104.0 (90.3) | 71.1 (111.4) |
Data are expressed as the median (interquartile range), pg/ml.
The Mann–Whitney U-test was performed to compare the two groups.
The levels of cytokines in different disease stages
| Cytokine | PACG-E ( | PACG-A ( | PACG-L ( | |
|---|---|---|---|---|
| G-CSF | 0.9 (1.3) | 2.8 (21.7) | 0.8 (2.4) | |
| IL-6 | 1.5 (1.9) | 3.6 (13.9) | 1.7 (8.7) | 0.159 |
| IL-8 | 4.4 (3.8) | 8.8 (13.5) | 8.2 (5.7) | 0.107 |
| MCP-1 | 748.0 (365.0) | 964.0 (685.0) | 1068.5 (906.8) | |
| MCP-3 | 3.2 (2.1) | 3.2 (2.1) | 3.2 (1.9) | 0.957 |
| MDC | 36.4 (35.1) | 25.7 (25.4) | 34.5 (24.8) | 0.725 |
| MIP-1β | 7.0 (8.3) | 9.4 (9.5) | 2.9 (5.8) | 0.196 |
| VEGF | 99.3 (121.1) | 104.0 (90.1) | 126.5 (123.8) | 0.459 |
Abbreviations: PACG-E, PACG in early stage; PACG-A, PACG in advanced stage; PACG-L, PACG in late stage.
Data are expressed as the median (interquartile range), pg/ml.
Kruskal–Wallis test was performed to compare the three groups.
The levels of cytokines in different extents of PAS
| Cytokine | No synechia ( | ≤1/2 synechia ( | >1/2 synechia ( | |
|---|---|---|---|---|
| G-CSF | 0.7 (2.7) | 1.0 (1.4) | 1.3 (3.7) | 0.414 |
| IL-6 | 2.0 (3.2) | 1.5 (5.9) | 1.8 (9.3) | 0.926 |
| IL-8 | 6.3 (12.4) | 4.6 (3.7) | 8.3 (7.3) | 0.283 |
| MCP-1 | 789.1 (520.5) | 916.0 (392.5) | 1008.0 (598.0) | 0.350 |
| MCP-3 | 3.7 (1.6) | 3.2 (3.2) | 3.2 (2.1) | 0.547 |
| MDC | 44.8 (44.6) | 26.3 (28.3) | 35.4 (22.8) | 0.564 |
| MIP-1β | 6.5 (15.2) | 2.9 (8.4) | 6.8 (9.7) | 0.460 |
| VEGF | 94.3 (113.5) | 84.7 (112.0) | 121.0 (75.8) | 0.270 |
Abbreviation: PAS, peripheral anterior synechiae.
Data are expressed as the median (interquartile range), pg/ml.
Kruskal–Wallis test was performed to compare the three groups.
The influence of anti-glaucoma drugs on the levels of cytokines
| Cytokine | No-drugs ( | Combined ( | Prostaglandin ( | |
|---|---|---|---|---|
| G-CSF | 1.0 (1.3) | 0.7 (1.4) | 1.7 (9.1) | 0.298 |
| IL-6 | 1.6 (3.2) | 1.5 (1.1) | 4.2 (15.9) | 0.106 |
| IL-8 | 4.6 (3.2) | 5.8 (5.3) | 8.7 (7.1) | 0.136 |
| MCP-1 | 710.0 (644.0) | 895.0 (361.0) | 1042.5 (713.0) | 0.290 |
| MCP-3 | 3.2 (2.7) | 3.2 (2.1) | 4.2 (1.3) | 0.461 |
| MDC | 27.5 (19.7) | 43.1 (24.1) | 30.5 (37.7) | 0.458 |
| MIP-1β | 7.5 (10.1) | 2.9 (4.9) | 10.1 (11.8) | |
| VEGF | 99.3 (164.0) | 94.8 (70.3) | 116.5 (107.0) | 0.575 |
Combined: other anti-glaucoma drugs exclude the prostaglandin.
Data are expressed as the median(interquartile range), pg/ml.
Kruskal–Wallis test was performed to compare the three groups.
Aqueous cytokines of angle closure eyes in published literatures
| Patient/control | Method | Different cytokine | Literature |
|---|---|---|---|
| APAC/PACS | Multiplex bead immunoassay | G-CSF, IL-6, IL-8, MCP-1, MCP-3, MDC, MIP-1β, VEGF↑ | Du S, 2016 |
| APAC/cataract | Multiplex bead immunoassay | IL-6, IL-8, G-CSF, MCP-1, MCP-3, VEGF↑ | Huang W, 2014 |
| APAC/cataract | Magnetic bead immunoassay, ELISA | sCD44 and VEGF↑ | Chen S, 2015 |
| APAC/cataract | Cytometric bead assay system | IL-2, IL-5, MCP-1, TNF-α, IP-10↑ | Tong Y, 2017 |
| APAC/cataract | Multiplex bead immunoassay | IL-12, IL-15, IL-6, IL-27↑ | Liu YM, 2017 |
| APAC/PACG | Multiplex bead immunoassay | MCP-1, MCP-3↑ | Gao X, 2016 |
| PACG/cataract | Multiplexed cytokine analysis | IL-8, CXCL9↑ | Chua J, 2012 |
| PACG/cataract | Multiplex bead immunoassay | IL-8, eotaxin, IP-10, MIP-1β↑ IL-9, IL-17, IL-5, TNF-α, GM-CSF↓ | Duvesh R, 2017 |
| PACG/cataract | Cytometric bead assay system | – | Tong Y, 2017 |
| PACG/cataract | Multiplex bead immunoassay | MCP-3, MDC, VEGF↑ MCP-1, MIP-1β↓ | Our study |
Abbreviations: APAC, acute primary angle-closure; PACG, primary angle-closure glaucoma; PACS, primary angle-closure suspect.
Treatments of different PACG stages patients
| Stage | Treatment | ||
|---|---|---|---|
| No-drugs | Combined | Prostaglandin | |
| PACG-E | 9 | 6 | 2 |
| PACG-A | 1 | 2 | 8 |
| PACG-L | 1 | 7 | 4 |
Number represents the number of eyes.